Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant

Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant El-housseiny and Hoaallah Clinical and Translational Allergy 2013, 3(Suppl 1):P2 http://www.ctajournal.com/content/3/S1/P2 POSTER PRESENTATION Open Access Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant 1* 2 Lamia El-housseiny , Essam Hoaallah From EAACI International Severe Asthma Forum (ISAF 2012) Gothenburg, Sweden. 11-13 October 2012 Worldwide ~235 million people currently suffer from reduced eosinophils (P < 0.002) compared to the AC asthma. We searched the integrative medicine and the group. The expression of HDAC1 in AMs-näive was ancient cultures in the Middle East, Africa, and China for (87%), which was decreased in CA group to (8%). LE25- new anti-asthma treatment. LE25-0712 is an herbal extract 0712 restores HDAC1 expression in AMs of treated (formula under patent). Here, we used it to validate the asthma model (45%, P < 0.0001). In 15 chronic asth- old knowledge known, to treat acute allergic asthma mice matic patients, LE25-0712 exerts a dramatic improve- model. We also identify the effect of our novel extract on ment in the general condition in 100% of patients, as it the expression of AMs-HDAC1 (alveolar macrophages- relieves the obstructive airway condition, which leads to histone deacetylase1). We had proven in a previous study, complete spare of corticosteroids administration. deletion of HDAC1 had increased allergic airway inflam- mation and enhanced Th2 cytokine production in asthma Conclusion mice model. In asthmatic and COPD patients, PBMC- The novel LE25-0712 is an effective natural safe medic- HDAC level was reduced compared to healthy individual. inal extract for the prophylaxis of acute asthma disease In this study, we evaluated the effect of LE25-0712 on the in mice, as well as controlling the recurrent asthmatic expression level of AMs-HDAC1 in treated asthmatic attacks in chronic patients. The effectiveness and safety mice (TAM) model compared to asthmatic control (AC) administration of this extract give it the upper hand group. over the traditional corticosteroid treatment. Moreover it restores the HDAC1 expression in TAM groups, Methods which can be used as a follow up marker. We used the acute asthma model of C57BL/6 mice, i.p. sensitized and i.n. challenged on d28, 29 with (OVA). Author details LE25-0712 (0.5 mg/kg) was i.n. administered b.i.d (d25- 1 Medical University of Vienna, Universitatsklinik for Chirurgie; Kardiovaskulare, 29). WE assayed bronchoalveolar lavage fluid (BALF) for Austria. National Research Center, Agriculture Microbiology Department, Egypt. the total and differential types of inflammatory cells, and the expression of HDAC1 by IMF (d31). Näive and AC Published: 3 May 2013 groups were included. As LE25-712 is a safe herbal supple- ment, allergic asthma patients were treated b.i.d by it com- bined with corticosteroid, until complete replacement of doi:10.1186/2045-7022-3-S1-P2 steroid. Cite this article as: El-housseiny and Hoaallah: Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant. Clinical and Translational Allergy 2013 3(Suppl 1):P2. Results LE25-0712 treatment of TAM group resulted in signifi- cant anti-inflammatory and anti- allergic activity as shown by reduced BAL total leukocytes (P < 0.03), and Medical University of Vienna, Universitatsklinik for Chirurgie; Kardiovaskulare, Austria Full list of author information is available at the end of the article © 2013 El-housseiny and Hoaallah; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Translational Allergy Springer Journals

Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant

Loading next page...
 
/lp/springer-journals/restoring-ams-hdac1-expression-in-allergic-asthma-mice-model-by-novel-k4p0PAbOh0

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2013 by El-housseiny and Hoaallah; licensee BioMed Central Ltd.
Subject
Medicine & Public Health; Allergology; Immunology
eISSN
2045-7022
DOI
10.1186/2045-7022-3-S1-P2
Publisher site
See Article on Publisher Site

Abstract

El-housseiny and Hoaallah Clinical and Translational Allergy 2013, 3(Suppl 1):P2 http://www.ctajournal.com/content/3/S1/P2 POSTER PRESENTATION Open Access Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant 1* 2 Lamia El-housseiny , Essam Hoaallah From EAACI International Severe Asthma Forum (ISAF 2012) Gothenburg, Sweden. 11-13 October 2012 Worldwide ~235 million people currently suffer from reduced eosinophils (P < 0.002) compared to the AC asthma. We searched the integrative medicine and the group. The expression of HDAC1 in AMs-näive was ancient cultures in the Middle East, Africa, and China for (87%), which was decreased in CA group to (8%). LE25- new anti-asthma treatment. LE25-0712 is an herbal extract 0712 restores HDAC1 expression in AMs of treated (formula under patent). Here, we used it to validate the asthma model (45%, P < 0.0001). In 15 chronic asth- old knowledge known, to treat acute allergic asthma mice matic patients, LE25-0712 exerts a dramatic improve- model. We also identify the effect of our novel extract on ment in the general condition in 100% of patients, as it the expression of AMs-HDAC1 (alveolar macrophages- relieves the obstructive airway condition, which leads to histone deacetylase1). We had proven in a previous study, complete spare of corticosteroids administration. deletion of HDAC1 had increased allergic airway inflam- mation and enhanced Th2 cytokine production in asthma Conclusion mice model. In asthmatic and COPD patients, PBMC- The novel LE25-0712 is an effective natural safe medic- HDAC level was reduced compared to healthy individual. inal extract for the prophylaxis of acute asthma disease In this study, we evaluated the effect of LE25-0712 on the in mice, as well as controlling the recurrent asthmatic expression level of AMs-HDAC1 in treated asthmatic attacks in chronic patients. The effectiveness and safety mice (TAM) model compared to asthmatic control (AC) administration of this extract give it the upper hand group. over the traditional corticosteroid treatment. Moreover it restores the HDAC1 expression in TAM groups, Methods which can be used as a follow up marker. We used the acute asthma model of C57BL/6 mice, i.p. sensitized and i.n. challenged on d28, 29 with (OVA). Author details LE25-0712 (0.5 mg/kg) was i.n. administered b.i.d (d25- 1 Medical University of Vienna, Universitatsklinik for Chirurgie; Kardiovaskulare, 29). WE assayed bronchoalveolar lavage fluid (BALF) for Austria. National Research Center, Agriculture Microbiology Department, Egypt. the total and differential types of inflammatory cells, and the expression of HDAC1 by IMF (d31). Näive and AC Published: 3 May 2013 groups were included. As LE25-712 is a safe herbal supple- ment, allergic asthma patients were treated b.i.d by it com- bined with corticosteroid, until complete replacement of doi:10.1186/2045-7022-3-S1-P2 steroid. Cite this article as: El-housseiny and Hoaallah: Restoring AMs-HDAC1 expression in allergic asthma mice model by novel medicinal plant. Clinical and Translational Allergy 2013 3(Suppl 1):P2. Results LE25-0712 treatment of TAM group resulted in signifi- cant anti-inflammatory and anti- allergic activity as shown by reduced BAL total leukocytes (P < 0.03), and Medical University of Vienna, Universitatsklinik for Chirurgie; Kardiovaskulare, Austria Full list of author information is available at the end of the article © 2013 El-housseiny and Hoaallah; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal

Clinical and Translational AllergySpringer Journals

Published: May 3, 2013

There are no references for this article.